Total Payments
$330,274
2024 Payments
$8,070
Companies
25
Transactions
288
Medicare Patients
895
Medicare Billing
$209,995
Payment Breakdown by Category
Consulting$242,552 (73.4%)
Other$41,853 (12.7%)
Travel$26,229 (7.9%)
Research$12,487 (3.8%)
Food & Beverage$7,131 (2.2%)
Education$21.74 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $242,552 | 110 | 73.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $33,048 | 19 | 10.0% |
| Travel and Lodging | $26,229 | 51 | 7.9% |
| Unspecified | $12,487 | 13 | 3.8% |
| Honoraria | $7,905 | 2 | 2.4% |
| Food and Beverage | $7,131 | 90 | 2.2% |
| Entertainment | $900.00 | 1 | 0.3% |
| Education | $21.74 | 2 | 0.0% |
Payments by Type
General
$317,787
275 transactions
Research
$12,487
13 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $56,893 | 58 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $39,554 | 32 | $0 (2024) |
| PFIZER INC. | $31,335 | 21 | $0 (2024) |
| Seagen Inc. | $28,108 | 21 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $26,277 | 31 | $0 (2023) |
| Janssen Global Services, LLC | $20,434 | 13 | $0 (2023) |
| Roche Products Limited | $19,047 | 8 | $0 (2018) |
| F. Hoffmann-La Roche AG | $17,870 | 19 | $0 (2023) |
| ABBVIE INC. | $14,849 | 9 | $0 (2024) |
| Seattle Genetics, Inc. | $13,370 | 15 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $8,070 | 18 | PFIZER INC. ($5,325) |
| 2023 | $43,636 | 34 | ABBVIE INC. ($14,734) |
| 2022 | $26,138 | 23 | Seagen Inc. ($9,522) |
| 2021 | $71,216 | 40 | E.R. Squibb & Sons, L.L.C. ($17,088) |
| 2020 | $33,168 | 26 | Janssen Global Services, LLC ($7,303) |
| 2019 | $42,892 | 48 | AstraZeneca Pharmaceuticals LP ($12,470) |
| 2018 | $70,758 | 60 | Roche Products Limited ($17,596) |
| 2017 | $34,396 | 39 | Merck Sharp & Dohme Corporation ($14,178) |
All Payment Transactions
288 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | PFIZER INC. | PADCEV (Biological) | — | In-kind items and services | $3,200.00 | Research |
| Study: PADCEV CLINICAL PUBLICATION PROGRAM • Category: Oncology | ||||||
| 12/03/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $135.00 | General |
| 12/03/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $30.00 | General |
| 12/03/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $30.00 | General |
| 09/18/2024 | Janssen Research & Development, LLC | — | Travel and Lodging | Cash or cash equivalent | $345.32 | General |
| 09/15/2024 | PFIZER INC. | — | — | In-kind items and services | $940.00 | Research |
| Study: NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM | ||||||
| 09/15/2024 | PFIZER INC. | PADCEV (Biological) | — | In-kind items and services | $940.00 | Research |
| Study: PADCEV CLINICAL PUBLICATION PROGRAM • Category: Oncology | ||||||
| 08/22/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $21.45 | General |
| Category: NONE | ||||||
| 06/02/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $51.79 | General |
| Category: ONC | ||||||
| 05/31/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $71.24 | General |
| Category: Oncology | ||||||
| 05/31/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $39.11 | General |
| Category: Oncology | ||||||
| 05/13/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $83.67 | General |
| 04/23/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $1,154.71 | General |
| 02/21/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $610.00 | General |
| Category: ONCOLOGY | ||||||
| 02/11/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $16.83 | General |
| Category: NONE | ||||||
| 01/25/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: ONCOLOGY | ||||||
| 01/25/2024 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $135.00 | General |
| 01/24/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $115.60 | General |
| 12/13/2023 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $1,430.00 | General |
| 12/02/2023 | Seagen Inc. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $93.50 | General |
| Category: Oncology | ||||||
| 11/17/2023 | Janssen Global Services, LLC | AKEEGA (Drug) | Food and Beverage | In-kind items and services | $131.57 | General |
| Category: Oncology | ||||||
| 08/16/2023 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,995.00 | General |
| 08/16/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $610.00 | General |
| Category: ONCOLOGY | ||||||
| 06/30/2023 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $452.62 | Research |
| Study: Immunomodulatory effects and improved outcomes with cisplatin- vs carboplatin-based chemotherapy plus atezolizumab in urothelial cancer • Category: BioOncology | ||||||
| 06/19/2023 | EMD Serono Research & Development Institute, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PADCEV CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,140 | 2 |
| SASANLIMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,530 | 2 |
| A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB ANTIPD-L1 ANTIBODY AS MONOTHERAPY AND IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA | F. Hoffmann-La Roche AG | $2,520 | 5 |
| NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| Immunomodulatory effects and improved outcomes with cisplatin- vs carboplatin-based chemotherapy plus atezolizumab in urothelial cancer | F. Hoffmann-La Roche AG | $452.62 | 1 |
| Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy combined with atezolizumab in urothelial cancerImmunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy combined with atezolizumab in urothelial cancer | F. Hoffmann-La Roche AG | $354.55 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 259 | 730 | $250,530 | $67,050 |
| 2022 | 3 | 192 | 590 | $179,660 | $48,775 |
| 2021 | 5 | 247 | 589 | $184,770 | $51,404 |
| 2020 | 3 | 197 | 599 | $195,350 | $42,766 |
Total Patients
895
Total Services
2,508
Medicare Billing
$209,995
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 114 | 518 | $160,580 | $45,151 | 28.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 36 | 36 | $24,120 | $5,978 | 24.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 16 | 35 | $14,350 | $3,798 | 26.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 31 | 65 | $13,000 | $3,552 | 27.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 22 | 32 | $13,760 | $2,664 | 19.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 16 | 19 | $8,360 | $2,510 | 30.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 11 | 12 | $9,600 | $1,897 | 19.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 13 | 13 | $6,760 | $1,501 | 22.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 101 | 426 | $131,840 | $36,918 | 28.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 46 | 112 | $22,400 | $6,214 | 27.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 34 | 34 | $17,680 | $4,100 | 23.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 11 | 18 | $7,740 | $1,542 | 19.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 98 | 358 | $110,980 | $32,160 | 29.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 57 | 123 | $24,600 | $7,357 | 29.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 23 | 29 | $12,760 | $3,618 | 28.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 26 | 26 | $13,520 | $3,351 | 24.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 11 | 11 | $7,370 | $1,926 | 26.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 17 | 24 | $10,320 | $1,925 | 18.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 15 | 18 | $5,220 | $1,067 | 20.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 121 | 508 | $157,480 | $35,516 | 22.6% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 28 | 28 | $14,560 | $3,341 | 22.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 27 | 36 | $15,480 | $2,655 | 17.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 21 | 27 | $7,830 | $1,253 | 16.0% |
About Dr. Matthew Galsky, MD
Dr. Matthew Galsky, MD is a Medical Oncology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1639140668.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Matthew Galsky, MD has received a total of $330,274 in payments from pharmaceutical and medical device companies, with $8,070 received in 2024. These payments were reported across 288 transactions from 25 companies. The most common payment nature is "Consulting Fee" ($242,552).
As a Medicare-enrolled provider, Galsky has provided services to 895 Medicare beneficiaries, totaling 2,508 services with total Medicare billing of $209,995. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location New York, NY
- Active Since 01/28/2006
- Last Updated 02/25/2019
- Taxonomy Code 207RX0202X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1639140668
Products in Payments
- TECENTRIQ (Biological) $42,148
- PADCEV (Biological) $28,263
- IMFINZI (Drug) $13,734
- KEYTRUDA (Biological) $12,160
- OPDIVO (Biological) $11,988
- BAVENCIO (Drug) $11,513
- Bavencio (Biological) $10,051
- Trodelvy (Drug) $7,702
- BALVERSA (Drug) $5,823
- ASG22 (Biological) $5,655
- Padcev (Drug) $4,340
- IMFINZI (Biological) $3,460
- PADCEV (Drug) $2,480
- Erleada (Drug) $2,265
- Bavencio (Drug) $2,250
- Tecentriq (Biological) $1,310
- SUTENT (Drug) $1,125
- ERLEADA (Drug) $1,048
- ENHERTU (Drug) $831.25
- AKEEGA (Drug) $131.57
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in New York
Craig Thompson, Md, MD
Medical Oncology — Payments: $2.1M
Medical Oncology $2.1M
Andrew Seidman, Md, MD
Medical Oncology — Payments: $1.7M
Medical Oncology $1.7M
Dr. Joshua Richter, M.d, M.D
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Ghassan Abou-Alfa, Md, MD
Medical Oncology — Payments: $1.2M
Medical Oncology $1.2M
Edward Gelmann
Medical Oncology — Payments: $944,679
Medical Oncology $944,679
Miguel Perales, Md, MD
Medical Oncology — Payments: $759,555
Medical Oncology $759,555